Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment

被引：0
|
作者：
Jinwei Zhang
机构：
[1] University of Exeter,Institute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences
[2] Hatherly Laboratories,State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics
[3] Shanghai Institute of Organic Chemistry,undefined
[4] Chinese Academy of Sciences,undefined
来源：
Inflammation Research | 2023年 / 72卷
关键词：
Alzheimer’s disease; Amyloid-beta; Lecanemab; Clinical trials; FDA approval drug;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and neuronal abnormalities. Current therapies address symptoms without altering disease progression. Lecanemab, an anti-amyloid antibody, binds to amyloid-beta (Aβ) protofibrils. Phase II trials revealed dose-dependent amyloid clearance and reduced clinical decline. Phase III trials demonstrated cognitive benefits with potential adverse events. Full FDA approval was granted for lecanemab due to its ability to eliminate toxic brain amyloids. However, longer trials are needed to assess its efficacy and safety. While lecanemab marks a significant advancement, further breakthroughs are essential for effective AD treatment.
引用
收藏
页码：1873 / 1876
页数：3
相关论文
共 50 条
12345